Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070050 | 0.79 | — | — | |
| SCHEMBL13636130 | 0.79 | CA5A (0.31) | — | |
| SCHEMBL18081341 | 0.78 | — | — | |
| SCHEMBL28815551 | 0.77 | CYP2D6 (0.33) | CYP2D6KDM4E | |
| SCHEMBL28026605 | 0.77 | CYP2D6 (0.33) | CYP2D6KDM4E | |
| Ammonia Solution, Strong SCHEMBL21625541 | 0.77 | CYP2D6 (0.33) | CYP2D6KDM4E | |
| Sulfuric Acid SCHEMBL28118371 | 0.77 | BLM (0.33) | CYP2D6KDM4E | |
| SCHEMBL15255389 | 0.75 | GRM4 (0.31) | — | |
| SCHEMBL17348048 | 0.74 | CYP2D6 (0.39) | CYP2D6KDM4E | |
| SCHEMBL496879 | 0.74 | SHBG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386947-B1 | METHOD FOR PRODUCING N-RETINOYLAMINOALKANE SULFONIC ACID | OASMIA PHARMACEUTICAL AB (SE) | 2021-05-19 | — | — | EP | disclosed |
| US-10322996-B2 | Method for producing N-retinoylcysteic acid alkyl ester | ARDENIA INVESTMENTS, LTD (GB) | 2019-06-18 | — | — | US | disclosed |
| WO-2017099662-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | ARDENIA INVESTMENTS, LTD. (GB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322996-B2 | Method for producing N-retinoylcysteic acid alkyl ester | AHCY, LRAT, RARA | CYP2D6 1326/4885KDM4E 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.